In contrast, Bladt et al. [49] reported that the c-Met inhibitor MSC2156119J (EMD 1214063) combination with sorafenib did not improve efficacy in MHCC97H human HCC xenograft model and HuPrime model with human HCC explants. This evidence concerns the gene MET and hepatocellular carcinoma.